Computational Prediction and Biochemical Analyses of New Inverse Agonists for the CB1 Receptor

Human cannabinoid type 1 (CB1) G-protein coupled receptor is a potential therapeutic target for obesity. The previously predicted and experimentally validated ensemble of ligand-free conformations of CB1 [Scott, C. E. et al. Protein Sci.2013, 22, 101−11323184890; Ahn, K. H. et al. Proteins2013, 81, 1304–131723408552] are used here to predict the binding sites for known CB1-selective inverse agonists including rimonabant and its seven known derivatives. This binding pocket, which differs significantly from previously published models, is used to identify 16 novel compounds expected to be CB1 inverse agonists by exploiting potential new interactions. We show experimentally that two of these compounds exhibit inverse agonist properties including inhibition of basal and agonist-induced G-protein coupling activity, as well as an enhanced level of CB1 cell surface localization. This demonstrates the utility of using the predicted binding sites for an ensemble of CB1 receptor structures for designing new CB1 inverse agonists.

[1]  Oliver P. Ernst,et al.  Crystal structure of metarhodopsin II , 2011, Nature.

[2]  Jiyoung Heo,et al.  Predicted Structures and Dynamics for Agonists and Antagonists Bound to Serotonin 5-HT2B and 5-HT2C Receptors , 2011, J. Chem. Inf. Model..

[3]  A. Leslie,et al.  Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation , 2011, Nature.

[4]  W. Goddard,et al.  Structure prediction of G protein-coupled receptors and their ensemble of functionally important conformations. , 2012, Methods in molecular biology.

[5]  Mary E Abood,et al.  An aromatic microdomain at the cannabinoid CB(1) receptor constitutes an agonist/inverse agonist binding region. , 2003, Journal of medicinal chemistry.

[6]  R. Stevens,et al.  Structure of an Agonist-Bound Human A2A Adenosine Receptor , 2011, Science.

[7]  William A Goddard,et al.  The structure of human serotonin 2c G-protein-coupled receptor bound to agonists and antagonists. , 2008, Journal of molecular graphics & modelling.

[8]  F. Allen.  The Cambridge Structural Database: a quarter of a million crystal structures and rising. , 2002, Acta crystallographica. Section B, Structural science.

[9]  K. Ahn,et al.  Allosteric Modulator ORG27569 Induces CB1 Cannabinoid Receptor High Affinity Agonist Binding State, Receptor Internalization, and Gi Protein-independent ERK1/2 Kinase Activation* , 2012, The Journal of Biological Chemistry.

[10]  K. Ahn,et al.  Mutations of CB1 T210 produce active and inactive receptor forms: correlations with ligand affinity, receptor stability, and cellular localization. , 2006, Biochemistry.

[11]  M. Caron,et al.  RNA Editing Induces Variation in Desensitization and Trafficking of 5-Hydroxytryptamine 2c Receptor Isoforms* , 2004, Journal of Biological Chemistry.

[12]  Laurence J. Miller,et al.  Seven Transmembrane Receptors as Shapeshifting Proteins: The Impact of Allosteric Modulation and Functional Selectivity on New Drug Discovery , 2010, Pharmacological Reviews.

[13]  L. Devi,et al.  Regulation of CB1 cannabinoid receptor trafficking by the adaptor protein AP‐3 , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[14]  C. Beyer,et al.  Depression-like phenotype following chronic CB1 receptor antagonism , 2010, Neurobiology of Disease.

[15]  Caitlin E. Scott,et al.  Computationally‐predicted CB1 cannabinoid receptor mutants show distinct patterns of salt‐bridges that correlate with their level of constitutive activity reflected in G protein coupling levels, thermal stability, and ligand binding , 2013, Proteins.

[16]  Lei Wang,et al.  A cannabinoid receptor 1 mutation proximal to the DRY motif results in constitutive activity and reveals intramolecular interactions involved in receptor activation , 2006, Brain Research.

[17]  Gebhard F. X. Schertler,et al.  The structural basis of agonist-induced activation in constitutively active rhodopsin , 2011, Nature.

[18]  P. Casellas,et al.  Modulation of CB1 cannabinoid receptor functions after a long-term exposure to agonist or inverse agonist in the Chinese hamster ovary cell expression system. , 1998, The Journal of pharmacology and experimental therapeutics.

[19]  William A. Goddard,et al.  SuperBiHelix method for predicting the pleiotropic ensemble of G-protein–coupled receptor conformations , 2013, Proceedings of the National Academy of Sciences.

[20]  J. Shiloach,et al.  Structure of the agonist-bound neurotensin receptor , 2012, Nature.

[21]  D. Farrens,et al.  Cysteine residues in the human cannabinoid receptor: only C257 and C264 are required for a functional receptor, and steric bulk at C386 impairs antagonist SR141716A binding. , 2005, Biochemistry.

[22]  Ravinder Abrol,et al.  Bihelix: Towards de novo structure prediction of an ensemble of G‐protein coupled receptor conformations , 2012, Proteins.

[23]  Bartosz Trzaskowski,et al.  Predicted 3D structures for adenosine receptors bound to ligands: comparison to the crystal structure. , 2010, Journal of structural biology.

[24]  J. Elguero,et al.  The structure of Rimonabant in the solid state and in solution: an experimental and theoretical study. , 2009, European journal of medicinal chemistry.

[25]  S. McAllister,et al.  Biarylpyrazole inverse agonists at the cannabinoid CB1 receptor: importance of the C-3 carboxamide oxygen/lysine3.28(192) interaction. , 2006, Journal of medicinal chemistry.

[26]  Stephen Taylor,et al.  Molecular dynamics for very large systems on massively parallel computers: The MPSim program , 1997, J. Comput. Chem..

[27]  Caitlin E. Scott,et al.  Molecular basis for dramatic changes in cannabinoid CB1 G protein‐coupled receptor activation upon single and double point mutations , 2013, Protein science : a publication of the Protein Society.

[28]  K. Ahn,et al.  Dual Role of the Second Extracellular Loop of the Cannabinoid Receptor 1: Ligand Binding and Receptor Localization , 2009, Molecular Pharmacology.

[29]  R. Stevens,et al.  The 2.6 Angstrom Crystal Structure of a Human A2A Adenosine Receptor Bound to an Antagonist , 2008, Science.

[30]  S. Rasmussen,et al.  Crystal Structure of the β2Adrenergic Receptor-Gs protein complex , 2011, Nature.

[31]  B. Kobilka,et al.  Energy landscapes as a tool to integrate GPCR structure, dynamics, and function. , 2010, Physiology.

[32]  W. R. Ewing,et al.  Cannabinoid CB(1) receptor ligand binding and function examined through mutagenesis studies of F200 and S383. , 2011, European journal of pharmacology.

[33]  S. Rasmussen,et al.  Structure of a nanobody-stabilized active state of the β2 adrenoceptor , 2010, Nature.

[34]  J. Ballesteros,et al.  [19] Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors , 1995 .

[35]  W. L. Jorgensen,et al.  Development and Testing of the OPLS All-Atom Force Field on Conformational Energetics and Properties of Organic Liquids , 1996 .

[36]  J. Lange,et al.  Keynote review: Medicinal chemistry strategies to CB1 cannabinoid receptor antagonists. , 2005, Drug discovery today.

[37]  T. Bonner,et al.  A lysine residue of the cannabinoid receptor is critical for receptor recognition by several agonists but not WIN55212-2. , 1996, Molecular pharmacology.

[38]  R. Stevens,et al.  Structural Basis for Allosteric Regulation of GPCRs by Sodium Ions , 2012, Science.

[39]  W. Goddard,et al.  Flat-Bottom Strategy for Improved Accuracy in Protein Side-Chain Placements. , 2008, Journal of chemical theory and computation.

[40]  J. Rossier,et al.  Constitutive Endocytic Cycle of the CB1 Cannabinoid Receptor* , 2004, Journal of Biological Chemistry.

[41]  W. Goddard,et al.  Predicted structures of agonist and antagonist bound complexes of adenosine A3 receptor , 2011, Proteins.

[42]  C. Tate,et al.  Thermostabilisation of an Agonist-Bound Conformation of the Human Adenosine A2A Receptor , 2011, Journal of molecular biology.

[43]  W. Goddard,et al.  Novel purine-based fluoroaryl-1,2,3-triazoles as neuroprotecting agents: synthesis, neuronal cell culture investigations, and CDK5 docking studies. , 2011, Bioorganic & medicinal chemistry letters.

[44]  Hualiang Jiang,et al.  Agonist-bound structure of the human P2Y12 receptor , 2014, Nature.

[45]  M. Saraste,et al.  FEBS Lett , 2000 .

[46]  Marcus Elstner,et al.  The retinal conformation and its environment in rhodopsin in light of a new 2.2 A crystal structure. , 2004, Journal of molecular biology.

[47]  Zhiping Weng,et al.  Docking unbound proteins using shape complementarity, desolvation, and electrostatics , 2002, Proteins.

[48]  Jeffrey Skolnick,et al.  Assessment of programs for ligand binding affinity prediction , 2008, J. Comput. Chem..

[49]  Antti Poso,et al.  Development of a 3D model for the human cannabinoid CB1 receptor. , 2004, Journal of medicinal chemistry.

[50]  D. Kendall,et al.  Ligand Binding and Modulation of Cyclic AMP Levels Depend on the Chemical Nature of Residue 192 of the Human Cannabinoid Receptor 1 , 1998, Journal of neurochemistry.

[51]  D. Lynch,et al.  N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A) interaction with LYS 3.28(192) is crucial for its inverse agonism at the cannabinoid CB1 receptor. , 2002, Molecular pharmacology.

[52]  Oliver P. Ernst,et al.  Crystal structure of opsin in its G-protein-interacting conformation , 2008, Nature.

[53]  R. Friesner,et al.  Generalized Born Model Based on a Surface Integral Formulation , 1998 .

[54]  E. Novellino,et al.  Synthesis, cannabinoid receptor affinity, and molecular modeling studies of substituted 1-aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamides. , 2008, Journal of medicinal chemistry.

[55]  Michel Bouvier,et al.  Restructuring G-Protein- Coupled Receptor Activation , 2012, Cell.

[56]  S. L. Mayo,et al.  DREIDING: A generic force field for molecular simulations , 1990 .

[57]  J. Shim,et al.  Probing the Interaction of SR141716A with the CB1 Receptor* , 2012, The Journal of Biological Chemistry.

[58]  P. Soubrié,et al.  SR141716A, a potent and selective antagonist of the brain cannabinoid receptor , 1994, FEBS letters.

[59]  Bartosz Trzaskowski,et al.  Ligand- and mutation-induced conformational selection in the CCR5 chemokine G protein-coupled receptor , 2014, Proceedings of the National Academy of Sciences.

[60]  Nagarajan Vaidehi,et al.  HierVLS hierarchical docking protocol for virtual ligand screening of large-molecule databases. , 2004, Journal of medicinal chemistry.

[61]  William L. Jorgensen,et al.  Journal of Chemical Information and Modeling , 2005, J. Chem. Inf. Model..

[62]  A. Makriyannis,et al.  (-)-7′-Isothiocyanato-11-hydroxy-1′,1′-dimethylheptylhexahydrocannabinol (AM841), a High-Affinity Electrophilic Ligand, Interacts Covalently with a Cysteine in Helix Six and Activates the CB1 Cannabinoid Receptor , 2005, Molecular Pharmacology.

[63]  Daniel Fleischer,et al.  Mutation Studies of Ser7.39 and Ser2.60 in the Human CB1 Cannabinoid Receptor: Evidence for a Serine-Induced Bend in CB1 Transmembrane Helix 7 , 2007, Molecular Pharmacology.

[64]  Yanli Wang,et al.  PubChem: Integrated Platform of Small Molecules and Biological Activities , 2008 .

[65]  J. Wess,et al.  Activation and allosteric modulation of a muscarinic acetylcholine receptor , 2013, Nature.

[66]  A. Makriyannis,et al.  Mapping the Structural Requirements in the CB1 Cannabinoid Receptor Transmembrane Helix II for Signal Transduction , 2008, Journal of Pharmacology and Experimental Therapeutics.

[67]  E. Novellino,et al.  Binding of the hemopressin peptide to the cannabinoid CB1 receptor: structural insights. , 2010, Biochemistry.

[68]  Xavier Deupi,et al.  Conformational complexity of G-protein-coupled receptors. , 2007, Trends in pharmacological sciences.

[69]  M. Burghammer,et al.  Crystal structure of the human β2 adrenergic G-protein-coupled receptor , 2007, Nature.

[70]  J M Blaney,et al.  A geometric approach to macromolecule-ligand interactions. , 1982, Journal of molecular biology.

[71]  Patrick Scheerer,et al.  Crystal structure of the ligand-free G-protein-coupled receptor opsin , 2008, Nature.

[72]  Gebhard F. X. Schertler,et al.  Structure of a β1-adrenergic G-protein-coupled receptor , 2008, Nature.

[73]  H. Okayama,et al.  High-efficiency transformation of mammalian cells by plasmid DNA. , 1987, Molecular and cellular biology.